ANDA 76024, held by Fosun Pharma. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 76024 (Fluoxetine Hydrochloride), held by Fosun Pharma, was first approved by FDA on Jan 29, 2002, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2002 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 10MG BASE · tablet;oral | Fluoxetine Hydrochloride | Discontinued |
| Dec 5, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 20, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 24, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 13, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 12, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 29, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters